Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q1 2023 Earnings Conference Call May 2, 2023 4:30 PM ET

Company Participants

Todd Friedman - Director, Investor Relations

Christian Henry - President and Chief Executive Officer

Susan Kim - Chief Financial Officer

Conference Call Participants

Dan Brennan - TD Cowen

David Westenberg - Piper Sandler

Kyle Mikson - Canaccord Genuity

Tejas Savant - Morgan Stanley

Sung Ji Nam - Scotiabank

Julia Qin - JPMorgan

John Sourbeer - UBS

Ross Osborn - Cantor Fitzgerald

Operator

Good day and welcome to the PacBio First Quarter 2023 Earnings Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note this event is being recorded.

I would now like to turn the conference over to Todd Friedman, Senior Director of IR. Please go ahead.

Todd Friedman

Good afternoon and welcome to PacBio's first quarter 2023 earnings conference call. Earlier today, we issued a press release outlining the financial results, we will be discussing on today's call, a copy of which is available in the Investor section of our website at www.pacb.com or as furnished on Form 8-K on the Securities and Exchange Commission website at www.sec.gov.

With me today are Christian Henry, President and Chief Executive Officer and Susan Kim, Chief Financial Officer.

Before we begin, I'd like to remind you that on today's call, we will be making forward-looking statements, including statements regarding predictions, progress, estimates, plans, intentions, guidance, and others, including expectations regarding our financial guidance, our Revio and Onso systems and their commercialization plans, the future availability, uses, accuracy, coverage, advantages, quality or performance of, or benefits or expected benefits of using PacBio products or technologies, including our Revio and Onso systems, and expectations with respect to customer demand for our products and technologies and growth in our business.

You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks and uncertainties that could cause our actual results to differ materially than those projected or discussed, including those inherent in developing and commercializing new products.

We refer you to our documents that we filed with the SEC, including our most recent forms 10-Q and 10-K, and our recent press release to better understand the risks and uncertainties that could cause actual results to differ. We disclaim any obligation to update or revise these forward-looking statements except as required by law.